Suppressive effects of suhexiang wan on amyloid-β42-induced extracellular signal-regulated kinase hyperactivation and glial cell proliferation in a transgenic drosophila model of alzheimer's disease

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 3, 2013, Pages 390-398

  Park, Seung Hwan ^a   Lee, Soojin ^a   Hong, Yoon Ki ^a   Hwang, Soojin ^a   Lee, Jang Ho ^a   Bang, Se Min ^a   Kim, Young Kyoon ^b   Koo, Byung Soo ^c   Lee, Im Soon ^a   Cho, Kyoung Sang ^a  

^a Konkuk University   (South Korea)

^b Kookmin University   (South Korea)

^c Dongguk University   (South Korea)

Author keywords

Alzheimer's disease; Amyloid 42; Drosophila; Extracellular signal regulated kinase; Glial cell; SuHeXiang Wan

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CASPASE; CHINESE DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; KSOP 1009; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DROSOPHILA; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REPRESSION; GENE EXPRESSION; GLIA CELL; MALE; NONHUMAN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DROSOPHILA; DRUGS, CHINESE HERBAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; NEUROGLIA; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84875542751     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00792     Document Type: Article

References (48)

1. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron, 44, 181-193 (2004
2. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun., 120, 885-890 (1984
3. Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide- the first step of a fatal cascade. J. Neurochem., 91, 513-520 (2004
4. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 250, 279-282 (1990
5. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M. Neuron loss in APP transgenic mice. Nature, 395, 755-756 (1998
6. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature, 430, 631-639 (2004
7. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature, 410, 37-40 (2001
8. Zhu X, Lee HG, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals, 11, 270-281 (2002
9. Ma QL, Harris-White ME, Ubeda OJ, Simmons M, Beech W, Lim GP, Teter B, Frautschy SA, Cole GM. Evidence of Abeta- and transgene- dependent defects in ERK-CREB signaling in Alzheimer's models. J. Neurochem., 103, 1594-1607 (2007
10. Pearson AG, Byrne UT, MacGibbon GA, Faull RL, Dragunow M. Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains. Neurosci. Lett., 398, 246-250 (2006
11. Thakur A, Wang X, Siedlak SL, Perry G, Smith MA, Zhu X. c-Jun phosphorylation in Alzheimer disease. J. Neurosci. Res., 85, 1668-1673 (2007
12. Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW. CEP-1347/KT-7515, an inhibitor of SAPK/ JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J. Neurochem., 77, 849-863 (2001
13. Borsello T, Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr. Pharm. Des., 13, 1875-1886 (2007
14. Braithwaite SP, Schmid RS, He DN, Sung ML, Cho S, Resnick L, Monaghan MM, Hirst WD, Essrich C, Reinhart PH, Lo DC. Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease. Neurobiol. Dis., 39, 311-317 (2010
15. Hong YK, Park SH, Lee S, Hwang S, Lee MJ, Kim D, Lee JH, Han SY, Kim ST, Kim YK, Jeon S, Koo BS, Cho KS. Neuroprotective effect of SuHeXiang Wan in Drosophila models of Alzheimer's disease. J. Ethnopharmacol., 134, 1028-1032 (2011
16. Hong YK, Lee S, Park SH, Lee JH, Han SY, Kim ST, Kim YK, Jeon S, Koo BS, Cho KS. Inhibition of JNK/dFOXO pathway and caspases rescues neurological impairments in Drosophila Alzheimer's disease model. Biochem. Biophys. Res. Commun., 419, 49-53 (2012
17. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, Raina AK, Holbrook N, Siedlak SL, Harris PL, Smith MA. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport, 10, 2411-2415 (1999
18. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the two hit hypothesis. Mech. Ageing Dev., 123, 39-46 (2001
19. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci., 21, 4125-4133 (2001
20. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science, 270, 1326-1331 (1995
21. Cobb MH. MAP kinase pathways. Prog. Biophys. Mol. Biol., 71, 479-500 (1999
22. Mills J, Laurent Charest D, Lam F, Beyreuther K, Ida N, Pelech SL, Reiner PB. Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J. Neurosci., 17, 9415-9422 (1997
23. Desdouits-Magnen J, Desdouits F, Takeda S, Syu LJ, Saltiel AR, Buxbaum JD, Czernik AJ, Nairn AC, Greengard P. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogenactivated protein kinase cascade. J. Neurochem., 70, 524-530 (1998
24. Cheung EC, Slack RS. Emerging role for ERK as a key regulator of neuronal apoptosis. Sci. STKE, 2004, PE45 (2004
25. Subramaniam S, Zirrgiebel U, von Bohlen Und Halbach O, Strelau J, Laliberté C, Kaplan DR, Unsicker K. ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J. Cell Biol., 165, 357-369 (2004
26. Ji RR, Befort K, Brenner GJ, Woolf CJ. ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J. Neurosci., 22, 478-485 (2002
27. Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain, 114, 149-159 (2005
28. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 21, 383-421 (2000
29. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease- a double-edged sword. Neuron, 35, 419-432 (2002
30. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell, 140, 918-934 (2010
31. Weitz TM, Town T. Microglia in Alzheimer's disease: It's all about context. Int. J. Alzheimer's Dis., 2012, 314185 (2012
32. Schwab C, Klegeris A, McGeer PL. Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim. Biophys. Acta, 1802, 889-902 (2010
33. Dahlgaard K, Jung A, Qvortrup K, Clausen H, Kjaerulff O, Wandall HH. Neurofibromatosis-like phenotype in Drosophila caused by lack of glucosylceramide extension. Proc. Natl. Acad. Sci. U.S.A. 109, 6987-6992 (2012
34. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology, 47, 425-432 (1996
35. Cole GM, Frautschy SA. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol. Disord. Drug Targets, 9, 140-148 (2010
36. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol., 9, 702-716 (2010
37. Bensky D, Gamble A. Chinese Herbal Medicine (Materia Medica), 1st ed., Eastland Press, Seattle (1986
38. Koo BS, Lee SI, Ha JH, Lee DU. Inhibitory effects of the essential oil from SuHeXiang Wan on the central nervous system after inhalation. Biol. Pharm. Bull., 27, 515-519 (2004
39. Kim KD, Jeong DG. Experimental Study on the change of stressrelated hormone contents by Kyogamdan and Sohaphyangwon. J. Orient. Neuropsychiatry, 3, 121-134 (1993
40. Jeon S, Bose S, Hur J, Jun K, Kim YK, Cho KS, Koo BS. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease. J. Ethnopharmacol., 137, 783-789 (2011
41. Lee MJ, Park SH, Han JH, Hong YK, Hwang S, Lee S, Kim D, Han SY, Kim ES, Cho KS. The effects of hempseed meal intake and linoleic acid on Drosophila models of neurodegenerative diseases and hypercholesterolemia. Mol. Cells, 31, 337-342 (2011
42. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature, 407, 802-809 (2000
43. Kurant E. Keeping the CNS clear: glial phagocytic functions in Drosophila. Glia, 59, 1304-1311 (2011
44. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature, 399 (Suppl.), A23-A31 (1999
45. Keller M, Enot DP, Hodson MP, Igwe EI, Deigner HP, Dean J, Bolouri H, Hagberg H, Mallard C. Inflammatory-induced hibernation in the fetus: priming of fetal sheep metabolism correlates with developmental brain injury. PLoS ONE, 6, e29503 (2011
46. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer's disease. Alzheimer Dis. Assoc. Disord., 22, 209-221 (2008
47. Parachikova A, Green KN, Hendrix C, LaFerla FM. Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS ONE, 5, e14015 (2010
48. Patel L, Grossberg GT. Combination therapy for Alzheimer's disease. Drugs Aging, 28, 539-546 (2011).,